News

Breckenridge filed an ANDA with the FDA in early 2006 and expects to receive FDA Approval and market the product in 2007. Breckenridge says it has an aggressive

The antibodies are intended as a form of passive immunization to promote clearance from the brain of the endogenous soluble Alzheimer’s toxin, beta-amyloid, where it accumulates and causes

The UK biotech said that it will recruit around 70 patients at major cancer centers in the US. The trial tests Antisoma’s anticancer aptamer AS1411 in patients with

The researchers looked at the role of the natural substance cholecystokinin (CCK) in modulating communication between cells in the brain. CCK, originally isolated from the digestive tract, is

In November 2006, Par entered into a supply and distribution agreement with AstraZeneca in the US to distribute metoprolol succinate extended release tablets, as a substitute for Toprol-XL.

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). The SPA is an agreement between Innovive and the FDA on the pivotal Phase II study

The drug, ARRY-380, is a selective, orally-active ErbB-2 inhibitor which has shown good efficacy in preclinical models of human breast cancer resulting in significant anti-tumor activity, according to

Hana Biosciences is developing and commercializing Marqibo under a licensing partnership agreement with Tekmira. Hana Biosciences is paying development costs and will also pay milestones to Tekmira based

In the study, rats treated with a single bolus injection of rat AKIi-5, Quark’s proprietary siRNA compound targeting the p53 gene, were significantly protected from ischemia/reperfusion-induced acute kidney